ELSEVIER

Toxicology 113 (1996) 361–362

TOXICOLOGY

Author index

Volume 113 (1996)

Acquvaella, J.F. **113,** 120
Albertini, R.J. **113,** 56
Ammenheusen, M.M. **113,** 84
Anderson, D. **113,** 120
Asgharian, B. **113,** 306

Baur, C. **113,** 300
Bechtold, W.E. **113,** 322
Bechtold, W.E. **113,** 100
Bechtold, W.E. **113,** 17
Bechtold, W.E **113,** 84
Becking, G. **113,** 56
Bird, M. **113,** 253
Bird, M.G. **113,** 2
Bird, M.J. **113,** 263
Birnbaum, L.S. **113,** 14
Blair, I.A. **113,** 331
Bleasdale, C. **113,** 290
Bolt, H.M. **113,** 328
Bolt, H.M. **113,** 294
Bolt, H.M. **113,** 356
Bond, J.A. **113,** 297
Bond, J.A. **113,** 306
Bond, J.A. **113,** 310
Bond, J.A. **113,** 314
Bond, J.A. **113,** 48
Bond, J.A. **113,** 106
Boogaard, P.J. **113,** 294
Boogaard, P. **113,** 48
Brinkworth, M.H. **113,** 120
Bus, J.S. **113,** 240
Bus, J. **113,** 253

Cagen, S.Z. **113,** 215
Capellmann, M. **113,** 294
Chaudhary, A.K. **113,** 331
Chou, B.J. **113,** 247
Christian, M.S. **113,** 137
Colagiovanni, D.B. **113,** 59
Cole, P **113,** 182
Cole, P. **113,** 190
Cowless, S.R. **113,** 146
Cox, L.A. **113,** 263
Cox, L.A. **113,** 253
Csanády, G.A. **113,** 300
Csanády, G.A. **113,** 278

Dahl, A.R. **113,** 17
Dahl, A.R. **113,** 273
Dahl, A.R. **113,** 322
Darroudi, F. **113,** 91
Delzell, E. **113,** 182
Delzell, E. **113,** 190
Dempoulos, N.A. **113,** 91
Denk, B. **113,** 322
de Zwart, F.A. **113,** 91
Divine, B.J. **113,** 169
Doerr, C.L. **113,** 336
Doerr, J.K. **113,** 128
Dosemeci, M. **113,** 100

Edwards, A.J. **113,** 120
Elfarra, A.A. **113,** 23

Fagen, J.M. **113,** 157
Fessler-Flesch, C.A. **113,** 157
Fielder, R.J. **113,** 221
Filser, J.G. **113,** 40
Filser, J.G. **113,** 278
Filser, J.G. **113,** 300

Gelder, G.V. **113,** 215
Golding, B.T. **113,** 290
Griffins, L. **113,** 253
Griffins, L. **113,** 263

Halperin, W.E. **113,** 157
Hartman, C.M. **113,** 169
Hartmann, M. **113,** 278
Hayes, R.B. **113,** 100
Hays, S.M. **113,** 231
Headerson, R. **113,** 100
Henderson, R.F. **113,** 17
Henderson, R.F. **113,** 322
Himmelstein, W. **113,** 48
Himmelstein, M.W. **113,** 306
Himmelstein, M.W. **113,** 318
Hindermeier, U. **113,** 294
Hollis, E.A. **113,** 128
Hovinga, M. **113,** 190
Hovinga, M. **113,** 182

Irons, R.D. **113,** 59

Jelitto, B. **113,** 294
Jelitto, B. **113,** 328
Johanson, G. **113,** 40
Julian, J. **113,** 182
Julian, J. **113,** 190
Kambouris, S.J. **113,** 328
Kauffmann, A. **113,** 278
Keller, D.A. **113,** 14
Kelsey, K.T. **113,** 84
Kessler, W. **113,** 278
Kilgerman, A.D. **113,** 336
Kirkovsky, L.I. **113,** 294
Kohn, M.C. **113,** 31
Koppikar, A.M. **113,** 203
Krause, R.J. **113,** 23
Kreuzer, P.E. **113,** 294
Kreuzer, P.E. **113,** 300

Larson, R. **113,** 182
Larson, R. **113,** 190
Leavens, T.L. **113,** 310
Legator, M.S. **113,** 84
Lin, Y.-p. **113,** 70

Macaluso, M. **113,** 190
Macaluso, M. **113,** 182
Macdonald, R.L.M. **113,** 215
Medinsky, M.A. **113,** 48
Medinsky, M.A. **113,** 318

Megens, H.J.J.J. **113,** 112
Melnick, R.L. **113,** 247
Meyer, K. **113,** 106
Miler, R.A. **113,** 24
Milholland, V.S. **113,** 336
Muir, D. **113,** 190
Muir, D.C.F. **113,** 182

Natragan, A.J. **113,** 91

Omenn, G.S. **113,** 5
O'Neill, J.P. **113,** 100
Osterman-Golkar, S. **113,** 77

Pup, J.D. **113,** 346
Paustenbach, D.J. **113,** 212
Peltonen, K **113,** 77
Penn, A. **113,** 351
Peltonen, K. **113,** 91
Persing, R.L. **113,** 253
Peterková, K. **113,** 91
Placke, M.E. **113,** 253
Plopper, C.G. **113,** 314
Pluta, L. **113,** 106
Pütz, C. **113,** 278

Raagan, H.A. **113,** 247
Randerath, K. **113,** 341
Raothman, 10p0 **113,** 100
Regio, L. **113,** 106
Reitman, F. **113,** 346
Reitz, R.H. **113,** 231
Richardson, K.A. **113,** 112
Rinsky, R.A. **113,** 157
Roycroft, J.H. **113,** 247
Rössner, P. **113,** 91
Ruder, A.M. **113,** 157

Saarikoski, S.T. **113,** 77
Sangaiah, R. **113,** 70
Sathiakumar, N. **113,** 182
Sathiakumar, N. **113,** 190
Schlosser, P.M. **113,** 318
Seaton, M.J. **113,** 314
Seaton, M. **113,** 48
Selver, R.R. **113,** 23
Shen, J.H. **113,** 278
Sielken, R.L. **113,** 231
Sills, R.C. **113,** 247
Sipes, I.G. **113,** 128
Sisk, S. **113,** 106
Sittert, A. **113,** 112
Small, R.D. **113,** 290
Smith, M.T. **113,** 100
Srám, R.J. **113,** 91
Šram, R. **113,** 77
Stei, P. **113,** 218
Stephanou, G. **113,** 91
Stillman, W.S. **113,** 59
Smith, S. **113,** 346
Snyder, A. **113,** 351
Sorsa, M. **113,** 77
Summer, S.C-J. **113,** 297
Sweeney, L.M. **113,** 318
Swenberg, J.A. **113,** 70

Taalman, B.D.F.M. **113,** 242
Tates, A.D. **113,** 91
Tennant, A.H. **113,** 336
Thornton-Manning, J.R. **113,** 322
Thornton-Manning, J.R. **113,** 17
Tretyakova, N.Y. **113,** 70
Turner, M.J. **113,** 297
Turner, M.J. **113,** 306

Upton, P.B. **113,** 70

Van Dam, F.J. **113,** 91
Vlachodimitropoulos, D. **113,** 91

Ward, E.M. **113,** 157
Ward, J.B. **113,** 84
Watson, W.P. **113,** 290
Webb, J.D. **113,** 112
Whorton, E.B. **113,** 84
Wiemels, J. **113,** 100
Wilson, J. **113,** 290

Xi, L. **113,** 100
Yao, M. **113,** 100
Yin, S. **113,** 100

Zhang, D. **113,** 100
Zhang, L. **113,** 100

ELSEVIER

Toxicology 113 (1996) 363–368

TOXICOLOGY

Subject index

Volume 113 (1996)

Adenine; Butadiene; Adducts; Guanine **113**, 70

Adducts; Risk assessment; Cancer; Biomarkers **113**, 203

Adducts; Butadiene; Guanine; Adenine **113**, 70

Adducts; Butadiene; Biomonitoring; Haemoglobin; Edman degradation **113**, 112

Air quality standard; 1,3-Butadiene; Genotoxic carcinogen **113**, 221

Biomarkers; Risk assessment; Cancer; Adducts **113**, 203

Butadiene; Cancer; Mortality; Epidemiology **113**, 157

Biomonitoring; Butadiene; Haemoglobin; Adducts; Edman degradation **113**, 112

Biological monitoring; *Hprt* mutation; Butadiene; Human; Occupational health **113**, 84

Butadiene; Cancer risk assessment; Probabilistic risk assessment; Comprehensive realism; Decision analysis; Distributions; Physiologically based pharmacokinetic models **113**, 231

Butadiene diepoxide (BDO_2); Butadiene (BD); Butadiene monoepoxide (BDO); Butadiene metabolism **113**, 17

Butadiene; Biological monitoring; *Hprt* mutation; Human; Occupational health **113**, 84

Butadiene; Carcinogens; Environmental; Longitudinal studies; Mortality; Neoplasms; Occupational diseases; Rubber manufacturing; Lymphohematopoietic cancer **113**, 169

Butadiene epoxides; Ovarian toxicity; Species variation **113**,

Butadiene; Risk assessment; Genotoxic; Commission on Risk Assessment and Risk Management **113**, 11

Butadiene metabolism; Butadiene (BD); Butadiene monoepoxide (BDO); Butadiene diepoxide (BDO_2) **113**, 17

Butadiene monoepoxide (BDO); Butadiene (BD); Butadiene diepoxide (BDO_2); Butadiene metabolism **113**, 17

Butadiene (BD); Butadiene monoepoxide (BDO); Butadiene diepoxide (BDO_2); Butadiene metabolism **113**, 17

Butadiene monoxide; 1,3-Butadiene; Diepoxybutane; Mercapturic acids; DNA adducts; Myeloperoxidase; Cytochrome P450; GSH-*S*-transferases **113**, 23

Butadiene; Dideoxycytidine; Radiation; Stem cells; Hematopoietic; Lymphoma; Colony-forming units assay **113**, 59

Butadiene; Adducts; Guanine; Adenine **113**, 70

Butadiene; Chromosomal aberrations; Hemoglobin adducts; Individual sensitivity; Metabolic polymorphism **113**, 77

Butadiene; Biomonitoring; Haemoglobin; Adducts; Edman degradation **113**, 112

Butadiene; Inhalation; Rats; Mice; Species differences; Epoxide metabolites; Glutathione depletion **113**, 306

Butadiene; Styrene; Physiologically based pharmacokinetic model; Mixture; Interactions **113**, 310

1,3-Butadiene; Butadiene monoxide; Diepoxybutane; Mercapturic acids; DNA adducts; Myeloperoxidase; Cytochrome P450; GSH-*S*-transferases **113**, 23

1,3-Butadiene; Toxicokinetic modeling; Parameter sensitivity **113**, 31

1,3-Butadiene; 1,2-Epoxybutene-3; Glutathione; Man; Mouse; PBPK model; Rat; Species extrapolation **113**, 40

1,3-Butadiene; Risk assessment; Metabolism; Physiologically based toxicokinetic models **113**, 48

1,3-Butadiene; Human lymphocytes; *Hprt* mutants; Chromosomal aberrations; Micronuclei; Comet assay **113**, 91

1,3-Butadiene; *Hprt* mutation; Occupation **113**, 100

1,3-Butadiene; In vivo mutation; Transgenic mice **113**, 106

1,3-Butadiene; Male-mediated F_1 effects; Mice; Inhalation exposure **113**, 120

1,3-Butadiene (BD); Carcinogenicity; Reproductive toxicity; Developmental toxicity **113**, 137

1,3-Butadiene; Epidemiology; Leukemia; Non-Hodgkin's lymphoma **113**, 148

1,3-Butadiene; Styrene; Leukemia; Carcinogenicity **113**, 182

1,3-Butadiene; Leukemia; Occupational exposure; Styrene; Synthetic rubber; Epidemiologic methods; Follow-up studies **113**, 190

1,3-Butadiene; Risk assessment; Exposure; Environmental; Occupational **113**, 212

1,3-Butadiene; Risk assessment; Cancer risk; Review **113**, 215

1,3-Butadiene; Genotoxic carcinogen; Air quality standard **113**, 221

1,3-Butadiene; ESR; Occupational; Risk assessment **113**, 226

1,3-Butadiene; 1,2-Epoxybutene-3; 1,2:3,4-Diepoxybutane; Hydrolysis; DNA alkylation **113**, 294

1,3-Butadiene; Carcinogenicity; 1,2:3,4-Diepoxybutane; Glutathione conjugation; Metabolism **113**, 297

1,3-Butadiene; 1,2-Epoxy-3-butene; 1,2:3,4-Diepoxybutane; Glutathione; Haemoglobin adducts; Rats; Mice; Humans; Toxicokinetics; Physiological toxicokinetic model **113**, 300

1,3-Butadiene; Lung; Metabolism; Rats; Mice **113**, 314

Cancer; Mortality; Epidemiology; Butadiene **113**, 157

Cancer; Risk assessment; Biomarkers; Adducts **113**, 203

Cancer risk; Risk assessment; 1,3-Butadiene; Review **113**, 215

Cancer risk assessment; Butadiene; Probabilistic risk assessment; Comprehensive realism; Decision analysis; Distributions; Physiologically based pharmacokinetic models **113**, 231

Carcinogenesis; Isoprene; Risk assessment; Dose metrics; Dose-response modeling **113**, 263

Carcinogenicity; 1,3-Butadiene; 1,2:3,4-Diepoxybutane; Glutathione conjugation; Metabolism **113**, 297

Carcinogenicity; 1,3-Butadiene (BD); Reproductive toxicity; Developmental toxicity **113**, 137

Carcinogenicity; 1,3-Butadiene; Styrene; Leukemia **113**, 182

Carcinogens; Environmental; Longitudinal studies; Mortality; Neoplasms; Occupational diseases; Rubber manufacturing; Butadiene; Lymphohematopoietic cancer **113**, 169

Chromosomal aberrations; Butadiene; Hemoglobin adducts; Individual sensitivity; Metabolic polymorphism **113**, 77

Chromosomal aberrations; 1,3-Butadiene; Human lymphocytes; *Hprt* mutants; Micronuclei; Comet assay **113**, 91

Colony-forming units assay; Butadiene; Dideoxycytidine; Radiation; Stem cells; Hematopoietic; Lymphoma**113**, 59

Comet assay; 1,3-Butadiene; Human lymphocytes; *Hprt* mutants; Chromosomal aberrations; Micronuclei **113**, 91

Commission on Risk Assessment and Risk Management?; Butadiene; Risk assessment; Genotoxic **113**, 11

Comprehensive realism; Butadiene; Cancer risk assessment; Probabilistic risk assessment; Decision analysis; Distributions; Physiologically based pharmacokinetic models **113**, 231

Cytochrome P450; 1,3-Butadiene; Butadiene monoxide; Diepoxybutane; Mercapturic acids; DNA adducts; Myeloperoxidase; GSH-*S*-transferases **113**, 23

Decision analysis; Distributions; Butadiene; Cancer risk assessment; Probabilistic risk assessment; Comprehensive realism; Physiologically based pharmacokinetic models **113**, 231

Developmental toxicity; 1,3-Butadiene (BD); Carcinogenicity; Reproductive toxicity **113**, 137

Dideoxycytidine; Butadiene; Radiation; Stem cells; Hematopoietic; Lymphoma; Colony-forming units assay **113**, 59

Diepoxybutane; 1,3-Butadiene; Butadiene monoxide; Mercapturic acids; DNA adducts; Myeloperoxidase; Cytochrome P450; GSH-*S*-transferases **113**, 23

DNA adducts; 1,3-Butadiene; Butadiene monoxide; Diepoxybutane; Mercapturic acids; Myeloperoxidase; Cytochrome P450; GSH-*S*-transferases **113**, 23

1,2:3,4-Diepoxybutane; 1,3-Butadiene; 1,2-Epoxybutene-3; Hydrolysis; DNA alkylation **113**, 294

1,2:3,4-Diepoxybutane; 1,3-Butadiene; Carcinogenicity; Glutathione conjugation; Metabolism **113**, 297

1,2:3,4-Diepoxybutane; 1,3-Butadiene; 1,2-Epoxy-3-butene; Glutathione; Haemoglobin adducts; Rats; Mice; Humans; Toxicokinetics; Physiological toxicokinetic model **113**, 300

Dose metrics; Isoprene; Risk assessment; Carcinogenesis; Dose-response modeling **113**, 263

Dose-response modeling; Isoprene; Risk assessment; Carcinogenesis; Dose metrics; **113**, 263

DNA alkylation; 1,3-Butadiene; 1,2-Epoxybutene-3; 1,2:3,4-Diepoxybutane; Hydrolysis **113**, 294

Edman degradation; Butadiene; Biomonitoring; Haemoglobin; Adducts **113**, 112

Endogenous production; Isoprene; 2-Methyl-1,3-butadiene; Toxicokinetics; Physiological toxicokinetic model; Rat; Mouse; Man **113**, 278

Environmental; Carcinogens; Longitudinal studies; Mortality; Neoplasms; Occupational diseases; Rubber manufacturing; Butadiene; Lymphohematopoietic cancer **113**, 169

Environmental; 1,3-Butadiene; Risk assessment; **Exposure; Occupational** **113**, 212

Epidemiology; 1,3-Butadiene; Leukemia; Non-Hodgkin's lymphoma **113**, 148

Epidemiology; Cancer; Mortality; Butadiene **113**, 157

Epidemiologic methods; Leukemia; Occupational exposure; 1,3-Butadiene; Styrene; Synthetic rubber; Follow-up studies **113**, 190

ESR; 1,3-Butadiene; Occupational; Risk assessment **113**, 226

Epoxide metabolites; Butadiene; Inhalation; Rats; Mice; Species differences; Glutathione depletion **113**, 306

Ethenyloxirane; 2-Ethenyl-2-methyloxirane; Nucleophile; Regioselectivity **113**, 290

1,2-Epoxybutene-3; 1,3-Butadiene; 1,2:3,4-Diepoxybutane; Hydrolysis; DNA alkylation **113**, 294

1,2-Epoxy-3-butene; 1,3-Butadiene; 1,2:3,4-Diepoxybutane; Glutathione; Haemoglobin adducts; Rats; Mice; Humans; Toxicokinetics; Physiological toxicokinetic model **113**, 300

1,2-Epoxybutene-3; 1,3-Butadiene; Glutathione; Man; Mouse; PBPK model; Rat; Species extrapolation **113**, 40

2-Ethenyl-2-methyloxirane; Ethenyloxirane; Nucleophile; Regioselectivity **113**, 290

Follow-up studies; Leukemia; Occupational exposure; 1,3-Butadiene; Styrene; Synthetic rubber; Epidemiologic methods **113**, 190

Forestomach neoplasia; Isoprene; Lung neoplasia; Liver neoplasia; Macrocytic anemia **113**, 247

Genotoxic carcinogen; 1,3-Butadiene; Air quality standard **113**, 221

Genotoxic; Butadiene; Risk assessment; Commission on Risk Assessment and Risk Management **113**, 11

Glutathione; 1,3-Butadiene; 1,2-Epoxy-3-butene; 1,2:3,4-Diepoxybutane; Haemoglobin adducts; Rats; Mice; Humans; Toxicokinetics; Physiological toxicokinetic model **113**, 300

Glutathione conjugation; 1,3-Butadiene; Carcinogenicity; 1,2:3,4-Diepoxybutane; Metabolism **113**, 297

Glutathione depletion; Butadiene; Inhalation; Rats; Mice; Species differences; Epoxide metabolites **113**, 306

Glutathione; 1,3-Butadiene; 1,2-Epoxybutene-3; Man; Mouse; PBPK model; Rat; Species extrapolation **113**, 40

GSH-*S*-transferases; 1,3-Butadiene; Butadiene monoxide; Diepoxybutane; Mercapturic acids; DNA adducts; Myeloperoxidase; Cytochrome P450 **113**, 23

Guanine; Butadiene; Adducts; Adenine **113**, 70

Haemoglobin; Butadiene; Biomonitoring; Adducts; Edman degradation **113**, 112

Haemoglobin adducts; 1,3-Butadiene; 1,2-Epoxy-3-butene; 1,2:3,4-Diepoxybutane; Glutathione; Rats; Mice; Humans; Toxicokinetics; Physiological toxicokinetic model **113**, 300

Hematopoietic; Butadiene; Dideoxycytidine; Radiation; Stem cells; Lymphoma; Colony-forming units assay **113**, 59

Hemoglobin adducts; Butadiene; Chromosomal aberrations; Individual sensitivity; Metabolic polymorphism **113**, 77

***Hprt* mutation;** Biological monitoring; Butadiene; Human; Occupational health **113**, 84

***Hprt* mutants;** 1,3-Butadiene; Human lymphocytes; Chromosomal aberrations; Micronuclei; Comet assay **113**, 91

***Hprt* mutation;** 1,3-Butadiene; Occupation **113**, 100

Human lymphocytes; 1,3-Butadiene; *Hprt* mutants; Chromosomal aberrations; Micronuclei; Comet assay **113**, 91

Humans; 1,3-Butadiene; 1,2-Epoxy-3-butene; 1,2:3,4-Diepoxybutane; Glutathione; Haemoglobin adducts; Rats; Mice; Toxicokinetics; Physiological toxicokinetic model **113**, 300

Human; Biological monitoring; *Hprt* mutation; Butadiene; Occupational health **113**, 84

Hydrolysis; 1,3-Butadiene; 1,2-Epoxybutene-3; 1,2:3,4-Diepoxybutane; DNA alkylation **113**, 294

Individual sensitivity; Butadiene; Chromosomal aberrations; Hemoglobin adducts; Metabolic polymorphism **113**, 77

Inhalation; Isoprene; Oncogenicity; Mice **113**, 253

Inhalation; Butadiene; Rats; Mice; Species differences; Epoxide metabolites; Glutathione depletion **113**, 306

Inhalation exposure; Male-mediated F_1 effects; Mice; 1,3-Butadiene **113**, 120

Interactions; Butadiene; Styrene; Physiologically based pharmacokinetic model; Mixture **113**, 310

In vivo mutation; 1,3-Butadiene; Transgenic mice **113**, 106

Isoprene; Occurrence; Production; Use; Toxicity **113**, 242

Isoprene; Lung neoplasia; Liver neoplasia; Forestomach neoplasia; Macrocytic anemia **113**, 247

Isoprene; Oncogenicity; Mice; Inhalation **113**, 253

Isoprene; Risk assessment; Carcinogenesis; Dose metrics; Dose-response modeling **113**, 263

Isoprene; Toxicokinetics; Metabolism in vivo **113**, 273

Isoprene; 2-Methyl-1,3-butadiene; Toxicokinetics; Physiological toxicokinetic model; Rat; Mouse; Man; Endogenous production **113**, 278

Leukemia; 1,3-Butadiene; Styrene; Carcinogenicity **113**, 182

Leukemia; 1,3-Butadiene; Epidemiology; Non-Hodgkin's lymphoma **113**, 148

Leukemia; Occupational exposure; 1,3-Butadiene; Styrene; Synthetic rubber; Epidemiologic methods; Follow-up studies **113**, 190

Liver neoplasia; Isoprene; Lung neoplasia; Forestomach neoplasia; Macrocytic anemia **113**, 247

Longitudinal studies; Carcinogens; Environmental; Mortality; Neoplasms; Occupational diseases; Rubber manufacturing; Butadiene; Lymphohematopoietic cancer **113**, 169

Lung; 1,3-Butadiene; Metabolism; Rats; Mice **113**, 314

Lung neoplasia; Isoprene; Liver neoplasia; Forestomach neoplasia; Macrocytic anemia **113**, 247

Lymphoma; Butadiene; Dideoxycytidine; Radiation; Stem cells; Hematopoietic; Colony-forming units assay **113**, 59

Lymphohematopoietic cancer; Carcinogens; Environmental; Longitudinal studies; Mortality; Neoplasms; Occupational diseases; Rubber manufacturing; Butadiene **113**, 169

Macrocytic anemia; Isoprene; Lung neoplasia; Liver neoplasia; Forestomach neoplasia **113**, 247

Male-mediated F_1 effects; Mice; Inhalation exposure; 1,3-Butadiene **113**, 120

Man; 1,3-Butadiene; 1,2-Epoxybutene-3; Glutathione; Mouse; PBPK model; Rat; Species extrapolation **113**, 40

Man; Isoprene; 2-Methyl-1,3-butadiene; Toxicokinetics; Physiological toxicokinetic model; Rat; Mouse; Endogenous production **113**, 278

Mercapturic acids; 1,3-Butadiene; Butadiene monoxide; Diepoxybutane; DNA adducts; Myeloperoxidase; Cytochrome P450; GSH-*S*-transferases **113**, 23

Metabolic polymorphism; Butadiene; Chromosomal aberrations; Hemoglobin adducts; Individual sensitivity **113**, 77

Metabolism; 1,3-Butadiene; Pharmacokinetics **113**, 14

Metabolism; 1,3-Butadiene; Risk assessment; Physiologically based toxicokinetic models **113**, 48

Metabolism in vivo; Isoprene; Toxicokinetics **113**, 273

Metabolism; 1,3-Butadiene; Carcinogenicity; 1,2:3,4-Diepoxybutane; Glutathione conjugation **113**, 297

Metabolism; 1,3-Butadiene; Lung; Rats; Mice **113**, 314

2-Methyl-1,3-butadiene; Isoprene; Toxicokinetics; Physiological toxicokinetic model; Rat; Mouse; Man; Endogenous production **113**, 278

Mice; Male-mediated F_1 effects; Inhalation exposure; 1,3-Butadiene **113**, 120

Mice; Isoprene; Oncogenicity; Inhalation **113**, 253

Mice; 1,3-Butadiene; 1,2-Epoxy-3-butene; 1,2:3,4-Diepoxybutane; Glutathione; Haemoglobin adducts; Rats; Humans; Toxicokinetics; Physiological toxicokinetic model **113**, 300

Mice; Butadiene; Inhalation; Rats; Species differences; Epoxide metabolites; Glutathione depletion **113**, 306

Mice; 1,3-Butadiene; Lung; Metabolism; Rats 113, 314

Micronuclei; 1,3-Butadiene; Human lymphocytes; *Hprt* mutants; Chromosomal aberrations; Comet assay **113**, 91

Mixture; Butadiene; Styrene; Physiologically based pharmacokinetic model; Interactions **113**, 310

Mortality; Cancer; Epidemiology; Butadiene **113**, 157

Mortality; Carcinogens; Environmental; Longitudinal studies; Neoplasms; Occupational diseases; Rubber manufacturing; Butadiene; Lymphohematopoietic cancer **113**, 169

Mouse; 1,3-Butadiene; 1,2-Epoxybutene-3; Glutathione; Man; PBPK model; Rat; Species extrapolation **113**, 40

Mouse; Isoprene; 2-Methyl-1,3-butadiene; Toxicokinetics; Physiological toxicokinetic model; Rat; Man; Endogenous production **113**, 278

Myeloperoxidase; 1,3-Butadiene; Butadiene monoxide; Diepoxybutane; Mercapturic acids; DNA adducts; Cytochrome P450; GSH-*S*-transferases **113**, 23

Neoplasms; Carcinogens; Environmental; Longitudinal studies; Mortality; Occupational diseases; Rubber manufacturing; Butadiene; Lymphohematopoietic cancer **113**, 169

Non-Hodgkin's lymphoma; 1,3-Butadiene; Epidemiology; Leukemia **113**, 148

Nucleophile; Ethenyloxirane; 2-Ethenyl-2-methyloxirane; Regioselectivity **113**, 290

Occupation; *Hprt* mutation; 1,3-Butadiene **113**, 100

Occupational diseases; Carcinogens; Environmental; Longitudinal studies; Mortality; Neoplasms; Rubber manufacturing; Butadiene; Lymphohematopoietic cancer **113**, 169

Occupational exposure; Leukemia; 1,3-Butadiene; Styrene; Synthetic rubber; Epidemiologic methods; Follow-up studies **113**, 190

Occupational; 1,3-Butadiene; Risk assessment; Exposure; Environmental **113**, 212

Occupational; 1,3-Butadiene; ESR; Risk assessment **113**, 226

Occupational health; Biological monitoring; *Hprt* mutation; Butadiene; Human **113**, 84

Occurrence; Isoprene; Production; Use; Toxicity **113**, 242

Oncogenicity; Isoprene; Mice; Inhalation **113**, 253

Ovarian toxicity; Butadiene epoxides; Species variation **113**,

Parameter sensitivity; 1,3-Butadiene; Toxicokinetic modeling **113**, 31

PBPK model; 1,3-Butadiene; 1,2-Epoxybutene-3; Glutathione; Man; Mouse; Rat; Species extrapolation **113**, 40

Pharmacokinetics; 1,3-Butadiene; Metabolism **113**, 14

Physiologically based pharmacokinetic models; Butadiene; Cancer risk assessment; Probabilistic risk assessment; Comprehensive realism; Decision analysis; Distributions **113**, 231

Physiologically based toxicokinetic models; 1,3-Butadiene; Risk assessment; Metabolism **113**, 48

Physiological toxicokinetic model; Isoprene; 2-Methyl-1,3-butadiene; Toxicokinetics; Rat; Mouse; Man; Endogenous production **113**, 278

Physiological toxicokinetic model; 1,3-Butadiene; 1,2-Epoxy-3-butene; 1,2:3,4-Diepoxybutane; Glutathione; Haemoglobin adducts; Rats; Mice; Humans; Toxicokinetics **113**, 300

Physiologically based pharmacokinetic model; Butadiene; Styrene; Mixture; Interactions **113**, 310

Probabilistic risk assessment; Butadiene; Cancer risk assessment; Comprehensive realism; Decision analysis; Distributions; Physiologically based pharmacokinetic models **113**, 231

Production; Use; Isoprene; Occurrence; Toxicity **113**, 242

Radiation; Butadiene; Dideoxycytidine; Stem cells; Hematopoietic; Lymphoma; Colony-forming units assay **113**, 59

Rat; 1,3-Butadiene; 1,2-Epoxybutene-3; Glutathione; Man; Mouse; PBPK model; Species extrapolation **113**, 40

Rat; Isoprene; 2-Methyl-1,3-butadiene; Toxicokinetics; Physiological toxicokinetic model; Mouse; Man; Endogenous production **113**, 278

Rats; 1,3-Butadiene; 1,2-Epoxy-3-butene; 1,2:3,4-Diepoxybutane; Glutathione; Haemoglobin adducts; Mice; Humans; Toxicokinetics; Physiological toxicokinetic model **113**, 300

Rats; Butadiene; Inhalation; Mice; Species differences; Epoxide metabolites; Glutathione depletion **113**, 306

Rats; 1,3-Butadiene; Lung; Metabolism; Mice **113**, 314

Review; Risk assessment; 1,3-Butadiene; Cancer risk **113**, 215

Regioselectivity; Ethenyloxirane; 2-Ethenyl-2-methyloxirane; Nucleophile **113**, 290

Reproductive toxicity; 1,3-Butadiene (BD); Carcinogenicity; Developmental toxicity **113**, 137

Risk assessment; Butadiene; Genotoxic; Commission on Risk Assessment and Risk Management **113**, 11

Risk assessment; 1,3-Butadiene; Metabolism; Physiologically based toxicokinetic models **113**, 48

Risk assessment; Cancer; Biomarkers; Adducts **113**, 203

Risk assessment; 1,3-Butadiene; Exposure; Environmental; Occupational **113**, 212

Risk assessment; 1,3-Butadiene; Cancer risk; Review **113**, 215

Risk assessment; Isoprene; Carcinogenesis; Dose metrics; Dose-response modeling **113**, 263

Risk assessment; 1,3-Butadiene; ESR; Occupational **113**, 226

Rubber manufacturing; Carcinogens; Environmental; Longitudinal studies; Mortality; Neoplasms; Occupational diseases; Butadiene; Lymphohematopoietic cancer **113**, 169

Species differences; Butadiene; Inhalation; Rats; Mice; Epoxide metabolites; Glutathione depletion **113**, 306

Species extrapolation; 1,3-Butadiene; 1,2-Epoxybutene-3; Glutathione; Man; Mouse; PBPK model; Rat **113**, 40

Species variation; Butadiene epoxides; Ovarian toxicity **113**,

Stem cells; Butadiene; Dideoxycytidine; Radiation; Hematopoietic; Lymphoma; Colony-forming units assay **113**, 59

Styrene; 1,3-Butadiene; Leukemia; Carcinogenicity **113**, 182

Styrene; Butadiene; Physiologically based pharmacokinetic model; Mixture; Interactions **113**, 310

Styrene; Leukemia; Occupational exposure; 1,3-Butadiene; Synthetic rubber; Epidemiologic methods; Follow-up studies **113**, 190

Synthetic rubber; Leukemia; Occupational exposure; 1,3-Butadiene; Styrene; Epidemiologic methods; Follow-up studies **113**, 190

Toxicokinetics; Isoprene; Metabolism in vivo **113**, 273

Toxicokinetics; Isoprene; 2-Methyl-1,3-butadiene; Physiological toxicokinetic model; Rat; Mouse; Man; Endogenous production **113**, 278

Toxicokinetics; 1,3-Butadiene; 1,2-Epoxy-3-butene; 1,2:3,4-Diepoxybutane; Glutathione; Haemoglobin adducts; Rats; Mice; Humans; Physiological toxicokinetic model **113**, 300

Toxicokinetic modeling; 1,3-Butadiene; Parameter sensitivity **113**, 31

Toxicity; Isoprene; Occurrence; Production; Use **113**, 242

Transgenic mice; 1,3-Butadiene; In vivo mutation **113**, 106

Use; Isoprene; Occurrence; Production; Toxicity **113**, 242